VERAXA Biotech AG (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to advance the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
According to the announcement, integrating artificial intelligence into VERAXA's research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
VERAXA's BiTAC platform represents a novel approach in cancer immunotherapy, utilizing bispecific T-cell engagers to direct the immune system's T-cells to attack cancer cells. By combining AI capabilities with its proprietary technology, VERAXA aims to overcome common challenges in oncology drug development, such as off-target effects and limited efficacy. The partnership with Ardigen, known for its expertise in AI and bioinformatics, is expected to accelerate the discovery of viable drug candidates.
The announcement highlights the growing trend of leveraging artificial intelligence in pharmaceutical research. AI can process vast amounts of data to uncover patterns that might be missed by traditional methods, potentially reducing the time and cost associated with drug development. For VERAXA, this collaboration could be pivotal in advancing its pipeline toward clinical trials and eventually to market.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is committed to building a premier engine for the discovery and development of next-generation antibody-based therapeutics. The company's pipeline includes bispecific T-cell engagers, bispecific ADCs, and other innovative formats, all guided by rigorous quality-by-design principles.
For more details, the full press release is available at https://ibn.fm/GLFg2. More information about VERAXA and its latest news can be found at http://ibn.fm/VRXA.
